Skip to main content
Sanofi (EPA:SAN)
France flag France · Delayed Price · Currency is EUR
97.18
-0.74 (-0.76%)
May 5, 2025, 10:45 AM CET

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Vaccine
8.45B
Log In
Log In
Log In
Log In
Total Vaccine Growth
12.87%
Log In
Log In
Log In
Log In
Total Pharmaceutical
-
Log In
Log In
Log In
Log In
Total Pharmaceutical Growth
-
Log In
Log In
Log In
Log In
Opella Consumer Healthcare
-
Log In
Log In
Log In
Log In
Opella Consumer Healthcare Growth
-
Log In
Log In
Log In
Log In
Dupixent
13.72B
Log In
Log In
Log In
Log In
Dupixent Growth
22.10%
Log In
Log In
Log In
Log In
Total Neurology & Immunology
-
Log In
Log In
Log In
Log In
Total Neurology & Immunology Growth
-
Log In
Log In
Log In
Log In
Total Rare Diseases
-
Log In
Log In
Log In
Log In
Total Rare Diseases Growth
-
Log In
Log In
Log In
Log In
Total Oncology
-
Log In
Log In
Log In
Log In
Total Oncology Growth
-
Log In
Log In
Log In
Log In
Total Rare Blood Disorders
-
Log In
Log In
Log In
Log In
Total Rare Blood Disorders Growth
-
Log In
Log In
Log In
Log In
Total Core Assets
-
Log In
Log In
Log In
Log In
Total Core Assets Growth
-
Log In
Log In
Log In
Log In
Total Non-Core Assets
-
Log In
Log In
Log In
Log In
Total Non-Core Assets Growth
-
Log In
Log In
Log In
Log In
Industrial
-
Log In
Log In
Log In
Log In
Industrial Growth
-
Log In
Log In
Log In
Log In
BioPharma
42.07B
Log In
Log In
Log In
Log In
BioPharma Growth
-
Log In
Log In
Log In
Log In
Specialty Care
-
Log In
Log In
Log In
Log In
Pharma
33.62B
Log In
Log In
Log In
Log In

EBIT by Product

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Pharmaceutical Operating Income
-
Log In
Log In
Log In
Log In
Pharmaceutical Operating Income Growth
-
Log In
Log In
Log In
Log In
Vaccine Operating Income
-
Log In
Log In
Log In
Log In
Vaccine Operating Income Growth
-
Log In
Log In
Log In
Log In
Other Operating Income
-
Log In
Log In
Log In
Log In
Other Operating Income Growth
-
Log In
Log In
Log In
Log In
Consumer Healthcare Operating Income
-
Log In
Log In
Log In
Log In
Consumer Healthcare Operating Income Growth
-
Log In
Log In
Log In
Log In
Biopharma Operating Income
11.84B
Log In
Log In
Log In
Log In
Biopharma Operating Income Growth
8.40%
Log In
Log In
Log In
Log In
Opella Consumer Healthcare (Post-2022 Reporting) Operating Income
-
Log In
Log In
Log In
Log In
Other (Post-2022 Reporting) Operating Income
9.00M
Log In
Log In
Log In
Log In
Other (Post-2022 Reporting) Operating Income Growth
28.57%
Log In
Log In
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
United States
21.45B
Log In
Log In
Log In
Log In
United States Growth
14.32%
Log In
Log In
Log In
Log In
Europe
9.76B
Log In
Log In
Log In
Log In
Europe Growth
-5.17%
Log In
Log In
Log In
Log In
Rest of World
13.43B
Log In
Log In
Log In
Log In
Rest of World Growth
-5.78%
Log In
Log In
Log In
Log In